Drug
Zimberelimab
Zimberelimab: highest development phase Phase 3, developed by Arcus Biosciences, Gilead Sciences, United Therapeutics. 8 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Arcus Biosciences, Gilead Sciences, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Zimberelimab NCT05502237 | Phase 3 | Non-small Cell Lung Cancer |
| Zimberelimab NCT04791839 | Phase 2 | Non Small Cell Lung Cancer |
| Zimberelimab NCT05724563 | Phase 2 | Hepatobiliary Cancer |
| Zimberelimab NCT05130177 | Phase 2 | Melanoma |
| Zimberelimab (ZIM) NCT05633667 | Phase 2 | Lung Cancer |
| ZIMBERELIMAB NCT05419479 | Phase 1/2 | Pancreatic Cancer |
| Zimberelimab NCT04656535 | Phase 1 | Glioblastoma |
| Zimberelimab NCT04892875 | Phase 1 | Head and Neck Cancer |
Latest
No recent events.
Follow Zimberelimab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.